ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

A focused discussion on how ADT is used as the backbone of prostate cancer therapy across different prostate cancer risk groups and according to metastatic and castration sensitivity status.

EP: 1.How PSA Has Impacted the Use of ADT in Prostate Cancer

Now Viewing

EP: 2.ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

EP: 3.Understanding and Mitigating the Cardiometabolic Risks of ADT

EP: 4.Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

January 2023 AbbVie Inc. Company Confidential

Related Videos

Related Content

Advertisement

June 12th 2025

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

Madhur Nayan, MD, PhD

"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

June 9th 2025

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

Hannah Clarke

In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

June 5th 2025

GLP-1 agonist use is rising in men with prostate cancer

Benjamin P. Saylor

In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.

June 4th 2025

ARANOTE: Darolutamide improves HRQoL in mHSPC

Benjamin P. Saylor

Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo

Related Content

Advertisement

June 12th 2025

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

Madhur Nayan, MD, PhD

"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

June 9th 2025

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

Hannah Clarke

In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

June 5th 2025

GLP-1 agonist use is rising in men with prostate cancer

Benjamin P. Saylor

In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.

June 4th 2025

ARANOTE: Darolutamide improves HRQoL in mHSPC

Benjamin P. Saylor

Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo